Pierre Fabre Dermo-Cosmetique introduces Avène A-OXitive Antioxidant Defense Serum and Avène A-OXitive Antioxidant Water-Cream to fight against oxidative stress. Stable forms of time-released vitamin E and vitamin C work synergistically to defend against environmental aggressors without irritation. Both products contain hyaluronic acid to visibly plump and firm the skin and soothing Avène thermal spring water to soften and restore the skin’s balance. To preserve stability, each formula comes in an airless pump bottle. For more information, visit www.aveneusa.com.
Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Orencia (abatacept) for the treatment of adults with active psoriatic arthritis. Orencia is available in both intravenous and subcutaneous injection formulations. It should not be administered concomitantly with tumor necrosis factor antagonists and is not recommended for use with other biologic rheumatoid arthritis therapy. Orencia also is indicated for the treatment of adult rheumatoid arthritis and juvenile idiopathic arthritis. For more information, visit www.orenciahcp.com.
Janssen Biotech, Inc, announces US Food and Drug Administration approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tremfya is a biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Tremfya is administered as a 100-mg subcutaneous injection every 8 weeks, following 2 starter doses at weeks 0 and 4. Clinical studies documented skin clearance at week 16 and up to week 48. For more information, visit www.tremfyahcp.com.
If you would like your product included in Product News, please email a press release to the Editorial Office at [email protected]